Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

PubWeight™: 18.57‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 32066541)

Published in Lancet Oncol on February 14, 2020

Authors

Wenhua Liang1, Weijie Guan2, Ruchong Chen2, Wei Wang1, Jianfu Li1, Ke Xu1, Caichen Li1, Qing Ai1, Weixiang Lu1, Hengrui Liang1, Shiyue Li2, Jianxing He3

Author Affiliations

1: Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
2: Department of Respiratory Disease, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
3: Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China. Electronic address: drjianxing.he@gmail.com.

Associated clinical trials:

Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2 (ASTANA) | NCT04434261

Registry on NEN Patients and COVID-19 | NCT04444401

SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study | NCT04494776

Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection | NCT04513158

Articles citing this

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective. ESMO Open (2020) 2.01

Preparing African anticancer centres in the COVID-19 outbreak. Lancet Oncol (2020) 1.40

Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol (2020) 1.39

A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab. J Thorac Oncol (2020) 1.39

The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol (2020) 1.37

Risk of COVID-19 for patients with cancer. Lancet Oncol (2020) 1.07

Risk of COVID-19 for patients with cancer. Lancet Oncol (2020) 1.07

Managing patients with cancer in the COVID-19 era. Eur J Cancer (2020) 0.75

COVID-19: Crisis Management in Lung Cancer Surgery. Rev Port Cir Cardiotorac Vasc (2020) 0.75

COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Glob Oncol (2020) 0.75

COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors. Eur J Cancer (2020) 0.75

Cancer Center Recommendations to Mitigate COVID-19 Impact in Patients With Cancer: Low-Resource Settings Version. JCO Glob Oncol (2020) 0.75

COVID-19 More Frequent, Severe in Cancer Patients. Cancer Discov (2020) 0.75

Effect of the COVID-19 Pandemic on Cancer Clinician Decision Making: Known Knowns and Known Unknowns. Clin Oncol (R Coll Radiol) (2020) 0.75

Cancer Research Ethics and COVID-19. Oncologist (2020) 0.75

High-dose chemotherapy in a patient with coronavirus disease (COVID-19). Eur J Cancer (2020) 0.75

Full Spectrum of Cancer Patients in SARS-CoV-2 Infection Still Being Described. Clin Oncol (R Coll Radiol) (2020) 0.75

Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians. Blood Cells Mol Dis (2020) 0.75

VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. Eur Urol (2020) 0.75

Caring of cancer patients during COVID-19: A real-life challenge. Indian J Cancer (2020) 0.75

Specific pathways to prevent SARS-CoV-2 infection in case of repeated hospital admissions for radiotherapy. Pediatr Blood Cancer (2020) 0.75

Managing COVID-19 in Patients With Cancer: A Double Blow for Oncologists. JCO Oncol Pract (2020) 0.75